Author/Authors :
-، - نويسنده Department of Pharmacology and Toxicology, National Institute for Pharmaceutical Research and Development, PMB 21, Abuja, Nigeria Adzu, Bulus , -، - نويسنده Department of Medicinal Chemistry and Quality Control, National Institute for Pharmaceutical Research and Development, PMB 21, Abuja, Nigeria Mustapha, Kudirat Bola , -، - نويسنده African Institute of Biomedical Science and Technology (AiBST), Cnr Chinhoyi Str./Jason Moyo Ave. No. 9 at LAPF Centre, Harare, Zimbabwe Masimirembwa, Collen , -، - نويسنده Department of Medicinal Chemistry and Quality Control, National Institute for Pharmaceutical Research and Development, PMB 21, Abuja, Nigeria Obodozie, Obiageri , -، - نويسنده Department of Medicinal Chemistry and Quality Control, National Institute for Pharmaceutical Research and Development, PMB 21, Abuja, Nigeria Abdullahi Kirim, Rukaiyatu , -، - نويسنده Director General/Chief Executive Officer, National Institute for Pharmaceutical Research and Development, PMB 21, Abuja, Nigeria Gamaniel, Karniyus Shingu
Abstract :
Objective: To evaluate the effect of NIPRD-AM1 on CYP3A4 in order to generate clinically significant data for its safe and efficacious use. Materials and Methods: NIPRD-AM1 is a phytomedicine developed from aqueous root extracts of Nauclea latifolia Smith (Rubiaceae) for the treatment of uncomplicated malaria. The effect of NIPRD-AM1 on CYP3A4 was measured with and without the addition of NIPRD-AM1, by testing different concentrations of the product at 37 °C in reactive mixtures with ketoconazole (2.5 µM) as the positive control. Results: Results showed a very low IC50 value of 0.01 mg/ml similar to that of ketoconazole (0.016 mg/ml). Conclusion: Metabolic processes of NIPRD-AM1 are likely to inhibit CYP3A4, with potential implication on drugs that are CYP3A4 substrates. This is a promising approach for guidance towards the safe and efficacious use of NIPRD-AM1.
